[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476939":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":115,"collaborators":24,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":24,"eligibilityCriteria":123,"healthyVolunteers":119,"sex":124,"minAge":125,"maxAge":24,"enrollmentInfo":126,"targetDuration":24,"studyType":129,"phases":130,"briefSummary":133,"conditions":134,"keywords":140,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Jacobio Pharmaceuticals Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"JAB-2485 monotherapy, Phase 1, Dose Escalation","EXPERIMENTAL","Dose escalation of JAB-2485 will be administered as monotherapy to determine the MTD and RP2D.",[13],"Drug: JAB-2485 (Aurora A inhibitor)",{"label":15,"type":10,"description":16,"interventionNames":17},"JAB-2485 monotherapy, Phase 2a, Dose Expansion","JAB-2485 will be administered as monotherapy in patients with specific tumor types to evaluate the preliminary antitumor activity.",[13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","JAB-2485 (Aurora A inhibitor)","Administered orally",[9],null,{"type":20,"name":21,"description":22,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Jacobio Pharmaceuticals","CONTACT","(781) 918-6670","clinicaltrials@jacobiopharma.com",[34,48,58,68,78,90,95,105],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":24},"Henry Ford Health System","RECRUITING","Detroit","Michigan","48202","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-83.04575,42.33143,{"lat":46,"lon":45},{"facility":49,"status":36,"city":50,"state":51,"zip":52,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":24},"Washington University","St Louis","Missouri","63110",{"type":43,"coordinates":54},[55,56],-90.19789,38.62727,{"lat":56,"lon":55},{"facility":59,"status":36,"city":60,"state":61,"zip":62,"country":40,"countryCode":41,"cosmosGeoPoint":63,"geoPoint":67,"contacts":24},"Mary Crowley Cancer Research","Dallas","Texas","75230",{"type":43,"coordinates":64},[65,66],-96.80667,32.78306,{"lat":66,"lon":65},{"facility":69,"status":36,"city":70,"state":71,"zip":72,"country":40,"countryCode":41,"cosmosGeoPoint":73,"geoPoint":77,"contacts":24},"University of Utah Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"type":43,"coordinates":74},[75,76],-111.89105,40.76078,{"lat":76,"lon":75},{"facility":79,"status":36,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":24},"Cancer Hospital Chinese Academy of Medical Sciences","Beijing","Beijing Municipality","100101","China","CN",{"type":43,"coordinates":86},[87,88],116.39723,39.9075,{"lat":88,"lon":87},{"facility":91,"status":36,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":92,"geoPoint":94,"contacts":24},"Peking University Third Hospital",{"type":43,"coordinates":93},[87,88],{"lat":88,"lon":87},{"facility":96,"status":36,"city":97,"state":98,"zip":99,"country":83,"countryCode":84,"cosmosGeoPoint":100,"geoPoint":104,"contacts":24},"Jilin Cancer Hospital","Changchun","Jilin","130000",{"type":43,"coordinates":101},[102,103],125.32278,43.88,{"lat":103,"lon":102},{"facility":106,"status":36,"city":107,"state":108,"zip":109,"country":83,"countryCode":84,"cosmosGeoPoint":110,"geoPoint":114,"contacts":24},"Shandong Cancer Hospital","Jinan","Shandong","250117",{"type":43,"coordinates":111},[112,113],116.99722,36.66833,{"lat":113,"lon":112},{"type":116,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100476939","phase-1-jab-2485-activity-in-adult-patients-with-advanced-solid-tumors-100476939",false,"NCT05490472","JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","A Phase 1\u002F2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must be able to provide an archived tumor sample\n* Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor\n\n  * Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated\n* Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n* Must have at least 1 measurable lesion per RECIST v1.1\n* Must have adequate organ functions\n* Must be able to swallow and retain orally administered medication\n\nExclusion Criteria:\n\n* Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days\n* Active infection requiring systemic treatment within 7 days\n* Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV\n* Any severe and\u002For uncontrolled medical conditions\n* left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)\n* QT interval using Fridericia's formula (QTcF) interval \\>470 msec\n* Experiencing unresolved CTCAE 5.0 Grade \\>1 toxicities\n* Clinically significant eye disorders","ALL","18 Years",{"count":127,"type":128},102,"ESTIMATED","INTERVENTIONAL",[131,132],"PHASE1","PHASE2","This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.",[135,136,137,138,139],"Solid Tumors","ER+ Breast Cancer","Triple Negative Breast Cancer, TNBC","ARID1A Gene Mutation","Small Cell Lung Cancer, SCLC",[141,138],"Aurora A inhibitor","2026-01-07",{"date":144,"type":145},"2026-01-09","ACTUAL",{"date":147,"type":145},"2022-12-20",{"date":149,"type":128},"2027-08",{"name":5,"class":6},8]